AIMS: Maraviroc (UK-427 857), an antagonist of the CCR5 receptor with potent anti-HIV activity, was recently approved for use in treatment-experienced patients infected with CCR5-tropic HIV-1. The aim of this study was to evaluate the effect of selected commonly used antiretroviral therapy (ART) combinations on the pharmacokinetics of a single oral dose of maraviroc 300 mg in HIV-positive subjects compared with historical controls. METHODS: In this study, four cohorts of HIV-positive patients (n = 8 each) receiving one of the following combination therapies were recruited: cohort 1--efavirenz + Combivir (lamivudine/zidovudine); cohort 2--efavirenz + didanosine + tenofovir; cohort 3--nevirapine + lamivudine + tenofovir; cohort 4--Kaletra (lopinavir/ritonavir) + stavudine + lamivudine. Subjects continued on their prescribed ART and also received a single oral dose of maraviroc 300 mg. Serial blood samples and urine for determination of maraviroc pharmacokinetics were collected over 12 h postdose. Plasma pharmacokinetic parameters from this study were compared with historical data generated in HIV-positive subjects receiving maraviroc monotherapy in a Phase IIa study. RESULTS:A total of 29 subjects were recruited (eight each in cohorts 1-3, and five in cohort 4). The geometric mean ratios for AUC(12) and C(max) for each treatment group compared with maraviroc monotherapy were: 47% and 67% (cohort 1); 48% and 76% (cohort 2); 101% and 154% (cohort 3); and 265% and 180% (cohort 4), respectively. T(max) was similar in all treatment groups. Mean values for renal clearance ranged from 8.2 l h(-1) (cohort 1) to 13.2 l h(-1) (cohort 4). There were no renal clearance data collected in the comparator study. CONCLUSIONS: The results of this study support those previously seen in healthy volunteer studies that showed that efavirenz reduces maraviroc exposure, whereas lopinavir/ritonavir increases maraviroc exposure. These data also suggest that nevirapine does not lead to a clinically significant effect on maraviroc pharmacokinetics.
RCT Entities:
AIMS: Maraviroc (UK-427 857), an antagonist of the CCR5 receptor with potent anti-HIV activity, was recently approved for use in treatment-experienced patients infected with CCR5-tropic HIV-1. The aim of this study was to evaluate the effect of selected commonly used antiretroviral therapy (ART) combinations on the pharmacokinetics of a single oral dose of maraviroc 300 mg in HIV-positive subjects compared with historical controls. METHODS: In this study, four cohorts of HIV-positive patients (n = 8 each) receiving one of the following combination therapies were recruited: cohort 1--efavirenz + Combivir (lamivudine/zidovudine); cohort 2--efavirenz + didanosine + tenofovir; cohort 3--nevirapine + lamivudine + tenofovir; cohort 4--Kaletra (lopinavir/ritonavir) + stavudine + lamivudine. Subjects continued on their prescribed ART and also received a single oral dose of maraviroc 300 mg. Serial blood samples and urine for determination of maraviroc pharmacokinetics were collected over 12 h postdose. Plasma pharmacokinetic parameters from this study were compared with historical data generated in HIV-positive subjects receiving maraviroc monotherapy in a Phase IIa study. RESULTS: A total of 29 subjects were recruited (eight each in cohorts 1-3, and five in cohort 4). The geometric mean ratios for AUC(12) and C(max) for each treatment group compared with maraviroc monotherapy were: 47% and 67% (cohort 1); 48% and 76% (cohort 2); 101% and 154% (cohort 3); and 265% and 180% (cohort 4), respectively. T(max) was similar in all treatment groups. Mean values for renal clearance ranged from 8.2 l h(-1) (cohort 1) to 13.2 l h(-1) (cohort 4). There were no renal clearance data collected in the comparator study. CONCLUSIONS: The results of this study support those previously seen in healthy volunteer studies that showed that efavirenz reduces maraviroc exposure, whereas lopinavir/ritonavir increases maraviroc exposure. These data also suggest that nevirapine does not lead to a clinically significant effect on maraviroc pharmacokinetics.
Authors: Rob E Aarnoutse; Karin J T Grintjes; Denise S C Telgt; Michael Stek; Patricia W H Hugen; Peter Reiss; Peter P Koopmans; Yechiel A Hekster; David M Burger Journal: Clin Pharmacol Ther Date: 2002-01 Impact factor: 6.875
Authors: Gerd Fätkenheuer; Anton L Pozniak; Margaret A Johnson; Andreas Plettenberg; Schlomo Staszewski; Andy I M Hoepelman; Michael S Saag; Frank D Goebel; Jürgen K Rockstroh; Bruce J Dezube; Tim M Jenkins; Christine Medhurst; John F Sullivan; Caroline Ridgway; Samantha Abel; Ian T James; Mike Youle; Elna van der Ryst Journal: Nat Med Date: 2005-10-05 Impact factor: 53.440
Authors: Don K Walker; Samantha Abel; Pierre Comby; Gary J Muirhead; Angus N R Nedderman; Dennis A Smith Journal: Drug Metab Dispos Date: 2005-01-13 Impact factor: 3.922
Authors: A d'Arminio Monforte; A C Lepri; G Rezza; P Pezzotti; A Antinori; A N Phillips; G Angarano; V Colangeli; A De Luca; G Ippolito; L Caggese; F Soscia; G Filice; F Gritti; P Narciso; U Tirelli; M Moroni Journal: AIDS Date: 2000-03-31 Impact factor: 4.177
Authors: Douglas D Richman; Sally C Morton; Terri Wrin; Nicholas Hellmann; Sandra Berry; Martin F Shapiro; Samuel A Bozzette Journal: AIDS Date: 2004-07-02 Impact factor: 4.177
Authors: T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes Journal: Antimicrob Agents Chemother Date: 2011-09-26 Impact factor: 5.191
Authors: Lianhong Xu; Hongtao Liu; Bernard P Murray; Christian Callebaut; Melody S Lee; Allen Hong; Robert G Strickley; Luong K Tsai; Kirsten M Stray; Yujin Wang; Gerry R Rhodes; Manoj C Desai Journal: ACS Med Chem Lett Date: 2010-05-17 Impact factor: 4.345
Authors: Clifford G Banda; Fraction Dzinjalamala; Mavuto Mukaka; Jane Mallewa; Victor Maiden; Dianne J Terlouw; David G Lalloo; Saye H Khoo; Victor Mwapasa Journal: Antimicrob Agents Chemother Date: 2018-10-24 Impact factor: 5.191
Authors: Liusheng Huang; Vincent Carey; Jane C Lindsey; Florence Marzan; David Gingrich; Bobbie Graham; Linda Barlow-Mosha; Phionah K Ssemambo; Portia Kamthunzi; Sharon Nachman; Sunil Parikh; Francesca T Aweeka Journal: PLoS One Date: 2017-10-24 Impact factor: 3.240